Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Ganz

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Archives of Pediatrics & Adolescent Medicine|April 4, 2007
The lifetime distribution of the incremental societal costs of autismMichael L Ganz
Obesity Research|November 25, 2003
The economic evaluation of obesity interventions: its time has comeMichael L Ganz
Pediatrics|June 3, 2006
Mental health care services for children with special health care needs and their family members: prevalence and correlates of unmet needsMichael L Ganz, Shalini A Tendulkar
Journal of Medical Economics|June 24, 2021
In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113Michael Serbin, Charles Yonan, Michael L Ganz
Ophthalmology|September 12, 2006
Prevalence and correlates of children's diagnosed eye and vision conditionsMichael L Ganz, Ziming Xuan, David G Hunter
Advances in Therapy|March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims AnalysisRuth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Journal of Medical Economics|January 4, 2021
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesiaMichael L Ganz, Ameya Chavan, Rahul Dhanda, et al.
Journal of Medical Economics|December 23, 2014
Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritisMichael L Ganz, Brian Bekker Hansen, Xavier Valencia, et al.
Medical Care|July 25, 2006
Community preferences for health states associated with intimate partner violenceEve Wittenberg, Erika L Lichter, Michael L Ganz, et al.
American Health & Drug Benefits|May 4, 2017
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United StatesJoseph Lee, Ryan Pelkey, Julieanna Gubitosa, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Archives of Pediatrics & Adolescent Medicine|April 4, 2007
The lifetime distribution of the incremental societal costs of autismMichael L Ganz
Obesity Research|November 25, 2003
The economic evaluation of obesity interventions: its time has comeMichael L Ganz
Pediatrics|June 3, 2006
Mental health care services for children with special health care needs and their family members: prevalence and correlates of unmet needsMichael L Ganz, Shalini A Tendulkar
Journal of Medical Economics|June 24, 2021
In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113Michael Serbin, Charles Yonan, Michael L Ganz
Ophthalmology|September 12, 2006
Prevalence and correlates of children's diagnosed eye and vision conditionsMichael L Ganz, Ziming Xuan, David G Hunter
Advances in Therapy|March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims AnalysisRuth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Journal of Medical Economics|January 4, 2021
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesiaMichael L Ganz, Ameya Chavan, Rahul Dhanda, et al.
Journal of Medical Economics|December 23, 2014
Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritisMichael L Ganz, Brian Bekker Hansen, Xavier Valencia, et al.
Medical Care|July 25, 2006
Community preferences for health states associated with intimate partner violenceEve Wittenberg, Erika L Lichter, Michael L Ganz, et al.
American Health & Drug Benefits|May 4, 2017
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United StatesJoseph Lee, Ryan Pelkey, Julieanna Gubitosa, et al.
Pageof 6